PubMed Health⌕ Search

PubMed · 8477772

Should the contralateral testis be biopsied? Round table discussion.

Abstract

Testicular tumours are bilateral in 5.2% of cases although the incidence of bilaterality is affected by the mode of treatment of the primary tumour. A biopsy of the contralateral testis of testicular tumour patients will reveal carcinoma in situ in 5.5% of cases. In Denmark, most testicular tumour patients have a contralateral biopsy at the time of the primary orchidectomy, but in many countries general urologists and surgeons are not always aware of the advantages of simultaneous contralateral biopsy. Some specialist centres perform a contralateral biopsy as a secondary procedure once the patient has been referred. It has not been the policy in USA to take a contralateral biopsy at the initial orchidectomy, nor to offer a biopsy to patients after referral to a specialist centre. As a result of the discussions at this conference, urologists in USA will now be encouraged to take a contralateral biopsy at the time of initial surgery. If this is not performed, patients should be offered a biopsy after a full discussion of the advantages and possible side effects of the procedure so that informed consent can be given.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K M Grigor, M Rørth. 1993. Should the contralateral testis be biopsied? Round table discussion.. https://doi.org/10.1159/000474581

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Non-radical diagnostic biopsies do not negatively influence melanoma patient survival.

BACKGROUND: In fair-skinned Caucasian populations both the incidence and mortality rates of cutaneous melanoma have been increasing over the past decades. With adjuvant therapies still being under investigation, early detection is the only way to improve melanoma patient survival. The influence of incisional biopsies on melanoma patient survival has been discussed for many years. This study investigates both the influence of diagnostic biopsy type and the presence of residual tumor cells in the re-excision specimen on disease free and overall survival. METHODS: After (partial) removal of a pigmented skin lesion 471 patients were diagnosed with stage I/II melanoma and underwent re-excision and a sentinel node biopsy. All patients were followed prospectively, mean follow up >5 years. Patients were divided according to their diagnostic biopsy type (wide excision biopsy, narrow excision biopsy, excision biopsy with positive margins and incisional biopsy) and the presence of residual tumor cells in their re-excision specimen. Survival analysis was done using Cox's proportional hazard model adjusted for eight important confounders of melanoma patient survival. RESULTS: The diagnostic biopsy was wide in 279 patients, narrow in 109 patients, 52 patients underwent an excision biopsy with positive margins and 31 patients an incisional biopsy. In 41 patients residual tumor cells were present in the re-excision specimen. Both the diagnostic biopsy type and the presence of tumor cells in the re-excision specimen did not influence disease free and overall survival of melanoma patients. CONCLUSIONS: Non-radical diagnostic biopsies do not negatively influence melanoma patient survival.

Biopsy↗